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Abstract
Amongst HIV-positive adults in South Africa with initialBackground: 
negative Xpert results, we compared the yield from repeating Xpert
MTB/RIF (“Xpert”) on sputum to guideline-recommended investigation for
tuberculosis (TB).
  A systematic sample of adults attending for HIV care wereMethods:
enrolled in a cohort exploring TB investigation pathways. This substudy was
restricted to those at highest risk of TB (CD4<200 cells/mm  or unknown)
who had a negative initial Xpert result.
At attendance for the Xpert result, a repeat sputum sample was stored, and
further investigations facilitated per national guidelines. Participants were
reviewed monthly, with reinvestigation if indicated, for at least three months,
when sputum and blood were cultured for mycobacteria, and the stored
sputum tested using Xpert. We defined TB as “confirmed” if Xpert, line
probe assay or  culture within six months ofMycobacterium tuberculosis 
enrolment were positive, and “clinical” if TB treatment was started without
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Any reports and responses or comments on the
article can be found at the end of the article.
enrolment were positive, and “clinical” if TB treatment was started without
microbiological confirmation.
Amongst 227 participants with an initial negative Xpert result (63%Results: 
female, median age 37 years, median CD4 count 100 cells/mm ), 28 (12%)
participants had TB diagnosed during study follow-up (16 confirmed, 12
clinical); stored sputum tested positive on Xpert in 5/227 (2%). Amongst 27
participants who started TB treatment, the basis was bacteriological
confirmation 11/27 (41%); compatible imaging 11/27 (41%); compatible
symptoms 2/27 (7%); and unknown 3/27 (11%). 
Amongst HIV-positive individuals at high risk of active TBConclusions:  
with a negative Xpert result, further investigation using appropriate
diagnostic modalities is more likely to lead to TB treatment than
immediately repeating sputum for Xpert. TB diagnostic tests with improved
sensitivity are needed.
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Introduction
Since 2011 the World Health Organization (WHO) has 
recommended Xpert MTB/RIF (Xpert; Cepheid, Sunnyvale, CA) 
as the initial diagnostic test for individuals being investigated 
for HIV-associated tuberculosis (TB)1. TB diagnosis in people 
living with HIV (PLHIV) is complicated by the high 
proportion who are smear-negative and/or have extrapulmo-
nary disease2. Although Xpert has superior sensitivity to sputum 
microscopy, it is less sensitive than culture, with a pooled 
sensitivity of 61% for smear-negative, culture-positive TB among 
PLHIV3.
South Africa replaced smear microscopy with Xpert start-
ing in 2011, for all individuals with symptoms suggesting TB4. 
Further evaluation of those who are HIV-positive and Xpert-
negative comprises clinical reassessment, chest radiograph if 
available, sputum for mycobacterial culture, and treatment with 
antibiotic if clinically indicated4. In a South African study of 
394 patients investigated for TB (irrespective of presence of 
symptoms) prior to antiretroviral therapy (ART) initiation, the 
sensitivity of Xpert for smear-negative, culture-positive TB 
increased from 43% to 62% when a second sample collected 
at the first visit was tested5. Mathematical modelling using a 
decision model from South Africa6 suggested that replacing 
sputum culture with the cheaper option of a second Xpert would 
reduce loss to follow-up so 1% more patients would start TB 
treatment7, and save an estimated US$17.4 million per year7. 
This model assumed, based on limited data, the same sensitivity 
for the second Xpert test as for the first7, guidelines would be 
correctly followed7, and only 1% of those with TB symptoms 
start TB treatment based on a clinical diagnosis6. The strategy 
of sending a repeat Xpert for HIV-positive individuals whose 
initial Xpert result is negative has not been evaluated empirically.
The aim of our study was, amongst HIV-positive adults being 
investigated for TB whose initial Xpert result is negative, to 
describe the diagnostic yield from an immediate repeat sputum 
tested with Xpert, compared to sequential further investigation 
guided by South African recommendations, reflecting pragmatic 
clinical practice.
Methods
This “repeat Xpert” substudy was part of “Xpert for people 
attending HIV/AIDS care: test or review?” (XPHACTOR), a 
prospective cohort study evaluating a risk-based algorithm to 
prioritise Xpert testing amongst adults attending for routine HIV 
care in South Africa8.
XPHACTOR study population, recruitment and procedures
XPHACTOR study flow, procedures and algorithm are described 
in detail in Supplementary File 1. In summary, we enrolled a 
systematic sample of adults (aged ≥18 years) attending four 
HIV clinics in Gauteng province, irrespective of presence of 
symptoms suggestive of TB, in the XPHACTOR study. Patients 
taking anti-tuberculosis treatment within the previous three 
months were excluded. Patients were enrolled into three groups: 
“on ART” (ART-experienced); “pre-ART” (in HIV care but 
not taking ART); and “HIV Testing and Counselling (HTC)” 
(newly-diagnosed HIV-positive). At the time of the study, ART 
eligibility comprised CD4 ≤350 cells/mm3 or WHO clinical 
stage ≥3. Research staff screened participants for TB at monthly 
intervals to three months, using a standardised questionnaire 
which incorporated the WHO symptom screen (any one of current 
self-reported cough, fever, weight loss or night sweats, hereafter 
the WHO tool). A spot sputum sample was collected for Xpert 
for individuals at a priori highest risk of active TB according to 
the study algorithm, which prioritised testing for those with any 
of: current cough, fever ≥ 3 weeks, night sweats ≥ 4 weeks, BMI 
<18.5 kg/m2, CD4 <100 cells/mm3, or weight loss ≥10%; and 
at enrolment from all in HTC group or pre-ART with CD4 
<200 cells/mm3 (Supplementary File 1). At enrolment all par-
ticipants with CD4 <200 cells/mm3 were asked to provide a spot 
urine sample, which was stored at 2–8°C prior to freezing at 
-80°C within 24 hours of collection. At the end of the study 
samples were thawed to ambient temperature and tested with 
lateral-flow LAM assay (LF-LAM; Determine TB-LAM; Alere, 
USA), and graded using the pre-January 2014 manufacturer’s 
reference card comprising five grades of colour intensity with 
the least intense band assigned grade 1, absence of a band graded 
negative, and absence of control band deemed a failed test.
At enrolment and follow-up visits, participants who submit-
ted an Xpert sample were reviewed within one week, and if 
Xpert-positive, TB treatment was initiated. If Xpert was negative, 
research staff repeated WHO symptom screen and facili-
tated the Xpert-negative algorithm for all who were WHO tool 
positive, which comprised chest radiograph, spot sputum for 
TB culture, and/or antibiotic trial as clinically appropriate. The 
Xpert-negative algorithm was also facilitated, because of 
a priori high risk of active TB, for all pre-ART participants 
with CD4<200x106/l who submitted sputum for immediate Xpert 
at enrolment to XPHACTOR.
At the three-month visit all participants had sputum and blood 
cultured for mycobacteria (Bactec MGIT 960 and 9240 systems). 
We allowed a broad window period around the three-month 
XPHACTOR main study final visit, until around six months, to 
maximise follow-up.
Repeat Xpert substudy procedures
XPHACTOR participants who were Xpert-negative with i) CD4 
count<200 cells/mm3 , or ii) new HIV diagnosis (HTC group) 
were eligible for this substudy, irrespective of presence of WHO 
tool symptoms; these restrictions aimed to minimise unnecessary 
testing of individuals at lower risk of active TB. If a participant 
had more than one negative Xpert result during follow-up, only 
the first episode was included.
At attendance for Xpert result review, eligible participants were 
asked for an additional spot sputum sample for “repeat” Xpert, 
which was frozen at -80°C within 24 hours of collection. All stored 
samples were thawed and tested with Xpert at the end of the study 
to evaluate the diagnostic yield that could have been achieved if an 
immediate repeat Xpert had been sent at the Xpert result review 
visit. We decided a priori not to induce sputum for this substudy in 
order to reflect what would be achievable in routine practice.
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Definitions
Repeat Xpert substudy entry and exit dates. Repeat Xpert 
substudy cohort entry date was defined as the date that the 
Xpert result review was conducted and sputum was collected for 
storage. Cohort exit date was defined as the last XPHACTOR study 
visit date.
TB case definitions. “Confirmed” TB was defined as a positive 
result on i) Xpert (on sputum sample) or ii) line probe assay 
(LPA) performed on smear-positive or cultured isolate (Geno-
Type MTBDRplus, Hain Lifesciences) or iii) Mycobacterium 
tuberculosis (Mtb) culture, from any sample (including stored 
sputum and those requested by health care providers) collected 
within six months of XPHACTOR enrolment. Clinical TB was 
defined as TB treatment started within six months of enrolment 
ascertained from clinical records, self or family report, or reported 
in the context of a separate verbal autopsy sub-study, in the 
absence of microbiological confirmation. Six months was chosen 
because TB disease evolves gradually;9,10 data from Zimbabwe 
estimated the mean duration of smear-positivity prior to TB 
diagnosis amongst HIV-positive adults at 18–33 weeks11.
“Not TB” was defined as absence of criteria for confirmed or 
clinical TB, and alive at least 3 months (the minimum follow-up 
period) after enrolment. Participants who did not fulfil the case 
definitions for TB or “not TB” were deemed to have unclassifiable 
outcome and excluded from analyses.
Pulmonary and extrapulmonary TB were classified in accordance 
with WHO definitions12. 
Radiological definitions. “Probable radiological TB” was defined 
as presence of any of cavitation, predominantly upper lobe 
infiltrates, pleural or pericardial effusion, or clear miliary picture 
on chest radiograph. “Possible radiological TB” was defined as 
presence of any of lymphadenopathy (hilar or mediastinal), pul-
monary nodules or other infiltrates. Participants with “probable” 
or “possible” radiological TB features, but without bacteriologi-
cal confirmation, who started TB treatment within six months 
of substudy enrolment were assigned as having “clinical” TB.
Statistical methods
Data were analysed using Stata 14 (Stata Corporation, College 
Station, TX, USA).
We did not undertake formal sample size calculation for this 
substudy as the sample size was all those eligible from the 
parent study.
We compared TB diagnoses made by Xpert using the sample 
stored at substudy enrolment, with all TB diagnoses fulfilling 
our case definitions during follow-up. We chose this pragmatic 
comparison because in real life, individuals with smear or 
Xpert-negative TB have sequential investigation, rather than all 
tests performed simultaneously. Our research staff facilitated 
the Xpert-negative algorithm when participants attended for 
Xpert result review, and therefore investigations are likely to have 
been initiated faster than in a routine setting. The proportion of TB 
diagnoses made by Xpert using the stored sputum was compared 
with TB diagnoses made during follow-up using McNemar’s test. 
In a sensitivity analysis restricted to participants who had at 
least one component of the Xpert-negative algorithm (chest 
radiograph, sputum for TB culture, or antibiotic trial) within a 
two-week window of providing the stored repeat Xpert sample, 
we compared the proportion of TB diagnoses made by Xpert using 
the stored sputum with TB diagnoses made by the Xpert-negative 
algorithm using McNemar’s test.
We calculated sensitivity and specificity with 95% confidence 
intervals (CI) for LF-LAM using a cut-off of grade =2+ to define 
LAM-positive against a diagnostic reference standard of 
confirmed plus clinical TB. We used the grade 2 cut-off as this 
corresponds with the grade 1 band in the current LF-LAM 
reference card, which is deemed a positive result in accordance 
with manufacturer’s recommendations13. 
Ethical approval
The study was approved by the ethics committees at the Univer-
sity of the Witwatersrand (approval # M120343), University of 
Cape Town (approval # 106/2012), and the London School of 
Hygiene & Tropical Medicine (approval # 6165). All consenting 
participants gave written consent or, witnessed verbal consent 
if unable to read or write. All ethics committees approved 
the consent form. Principles expressed in the Declaration of 
Helsinki were followed in the conduct of this research.
Results
Between September 2012 and March 2014, 235/410 (57.3%) 
potentially eligible participants were able to provide a sputum 
sample, stored for testing at study completion with Xpert 
(Figure 1). Eight participants with “unclassifiable” outcome 
were excluded, leaving 227 participants for analysis.
Participant characteristics
Characteristics of the 227 substudy participants and compari-
son with the 175 excluded because they were unable to produce 
sputum are presented in Table 1. The majority of participants 
were female (63%), median age was 37 years (interquartile 
range [IQR] 31,44), median CD4 count was 100 cells/mm3 (IQR 
51,147), and 26% had previously been treated for TB. 78/227 
(34%) of participants reported a TB symptom, most often cough 
(23%, 52/227) or weight loss (19%, 43/227) (Table 1). Amongst 
the remaining 149/227 (66%) of participants who reported no 
WHO-tool symptoms at attendance for Xpert result, sputum 
was collected for repeat Xpert due to a priori high risk of active 
TB because newly-diagnosed HIV-positive (42); pre-ART with 
CD4 count <200 cells/mm3 (42); CD4 count <100 cells/mm3 
(33); on ART with CD4 count 100–199 cells/mm3 (17); BMI 
<18.5 kg/m2 or weight loss ≥10%, (15). Enrolment to the repeat 
Xpert study was at median 7 days (IQR 7,8) from collection 
of the initial sputum sample for Xpert.
Tuberculosis diagnoses
12% (28/227) of substudy participants fulfilled case defini-
tions for TB, of which 16 were confirmed and 12 were clinical 
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Figure 1. Flow chart of repeat Xpert substudy participants. 1 15/175 who were excluded because they did not produce sputum fulfilled 
case definitions for TB (clinical TB [9/15], confirmed TB [6/15]) and a further 3/175 had unclassifiable outcome 2 For 22/235 participants who 
provided more than one “repeat” sample (all Xpert-negative) only the result of the first sample and data from the associated review visit were 
used in the analysis 3 All had negative “repeat” Xpert.
(Table 2). One participant died before TB treatment could be 
commenced, and for one, the treatment start date was unknown. 
The remaining 26 started TB treatment at a median 49 days 
(IQR 0,108) after substudy entry. The range for time from 
substudy entry to earliest of positive TB investigation (including 
chest radiograph) or date TB treatment was started (amongst 
all fulfilling our case definitions for TB) was 0–118 days. 24% 
(19/78) participants who were WHO tool positive when the 
sample for stored repeat Xpert was collected fulfilled TB case 
definitions (confirmed 11, clinical 8).
Basis for commencement of TB treatment. Eleven participants 
started treatment based on a bacteriologically-confirmed TB result 
(Xpert [7]; Mtb isolated from sputum [3] or blood [1]) (Table 2).
Eleven participants started TB treatment because of compat-
ible imaging. Nine had compatible chest radiographs, of whom 
four were subsequently bacteriologically confirmed (Xpert 2, 
pleural fluid cultured isolate LPA-positive 1, positive Mtb 
sputum culture 1). Two participants started treatment based on 
ultrasound scans, one compatible with abdominal TB (subse-
quently confirmed by positive Mtb from sputum culture); and 
the other showing pericardial effusion (Table 2).
Two participants started treatment because of compatible 
symptoms and positive sputum mycobacterial culture (later 
identified as non-tuberculous mycobacteria [NTM]) with 
symptomatic improvement on standard TB treatment. One par-
ticipant started TB treatment solely based on stored repeat Xpert 
sample. The basis for starting TB treatment was not clear for the 
remaining three participants (Table 2).
Diagnoses made by repeat Xpert on stored sputum samples. 
The stored sputum sample was positive by Xpert at the end 
of the study for five participants (sensitivity of repeat Xpert 
31.3% [5/16; 95% CI 11.0–58.7%] vs. gold standard of confirmed 
TB and 18% [5/28, 95% CI: 6.1%-36.9%] vs. gold standard 
of confirmed / clinical TB combined) (Figure 2). In a matched 
analysis the odds of TB diagnosis was much greater by other 
modalities during follow-up than by the repeat Xpert, odds ratio 
24.0 (95% CI: 3.9–986.9; p<0.0001, McNemar’s test). Amongst 
the five participants with positive repeat Xpert, three were in the 
pre-ART group, and two in the on ART group. We were unable 
to undertake multivariable analysis to look at independent 
predictors of positive repeat Xpert on the stored sample because 
only five were positive.
In a sensitivity analysis restricted to 123 participants who 
had at least one component of the Xpert-negative algorithm 
within a two-week window of providing the stored repeat Xpert 
sample, 23 participants fulfilled our TB case definitions (13/23 
confirmed, 10/23 clinical). The stored sputum sample was posi-
tive by Xpert for four participants (sensitivity of repeat Xpert 
for confirmed and clinical TB combined 17% [4/23]; for sputum 
culture-confirmed TB 20% [1/5]). Ten participants started TB 
treatment because of evaluation by the Xpert-negative algorithm 
(four confirmed, six clinical), of whom two also had positive 
stored repeat Xpert. Eleven other participants fulfilled TB case 
definitions during study follow-up (eight confirmed, three 
clinical). We did a matched analysis, classifying as “not TB” for 
the purpose of this analysis, 11 participants who fulfilled our 
TB case definitions but were not identified by either the Xpert- 
negative algorithm or stored repeat Xpert. The odds of TB 
diagnosis by the Xpert-negative algorithm was greater than by 
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Table 1. Characteristics of substudy participants (n=227) vs. eligible non-productive 
of sputum (n=175).
Characteristic Study participants 
(N=227)
Did not provide sputum 
for “repeat” Xpert (N=175)
N (%) N (%)
Demographics
Age, years - Median (IQR) 37 (31-44) (N=226) 36 (30-43)
Female 144 (63.4%) 109 (62.3%)
Black African 222 (97.8%) 175 (100%)
Participant category
On ART 99 (43.6%) 67 (38.3%)
Pre-ART 75 (33.0%) 60 (34.3%)
HTC 53 (23.4%) 48 (27.4%)
HIV/TB history
Previous TB treatment 59 (26.0%) 37 (21.1%)
Ever had IPT 18 (7.9%) 6 (3.4%)
Ever had CPT 122 (53.7%) 84 (48.0%)
BMI / CD4 when immediate Xpert was requested
BMI, kg/m2 - Median (IQR) 23.3 (20.1-27.4) (N=226) 23.4 (20.1-28.1)
CD41, cells/mm4 - Median (IQR) 100 (51-147) (N=188) 113 (56-169) (N=148)
WHO tool symptoms when sample for “repeat” Xpert was requested
WHO-positive 78 (34.4%) 44 (25.1%)
Cough 52 (22.9%) 23 (13.1%)
Weight loss 43 (18.9%) 32 (18.3%)
Night sweats 16 (7.0%) 9 (5.1%)
Fever 7 (3.1%) 2 (1.1%)
TB diagnoses over 6 months follow-up
Total 28 (12.3%) 18 (10.3%)
Confirmed TB 16 (7.1%) 7 (4.0%)
Clinical TB 12 (5.3%) 11 (6.3%)
Follow-up
Time from XPHACTOR 
enrolment to 3-month” study 
visit, days - Median (IQR)
84 (84,95) (N=220) 86 (84,106) (N=169)
Accuracy of LF-LAM for confirmed and clinical TB combined using Grade 2 cut-off
Prevalence of positive LAM, 
n/N (%)
2/142 (1.4%) 1/100 (1.0%)
Sensitivity n/N 0/18 0/9
Specificity n/N 
% (95% CI)
122/124  
98.4% (94.3, 99.8)
90/91  
98.9% (94.0, >99.9)
IPT= Isoniazid preventive therapy; BMI = body mass index; CPT= Cotrimoxazole preventive therapy; 
HTC= Enrolled from HIV testing and counselling service; WHO positive = self-report of any of current 
cough, fever, night sweats or unintentional weight loss.
1 Most recent clinic CD4 cell count when participant attended for Xpert result review. CD4 available 
for 188/227 participants enrolled (99/99 on ART, 75/75 pre-ART, 14/54 HTC); and 148/175 who did not 
provide sputum for repeat Xpert” (67/67 on ART, 60/60 pre-ART, 21/48 HTC)
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Table 2. Basis for TB diagnoses in repeat Xpert substudy (N=28).
Characteristic Participants 
diagnosed 
with TB N=28 
N (%)
Case definition
           Bacteriologically confirmed TB: 16 (57%)
Sputum Xpert positive1     6 (21%)
Sputum Mtb culture positive     4 (14%)
Sputum both Xpert and Mtb culture-positive     4 (14%)
Blood Mtb culture-positive     1 (4%)
Pleural fluid cultured isolate LPA-positive     1 (4%)
           Clinical TB: 12 (43%)
Site of TB
Pulmonary TB only 18 (64%)
Extrapulmonary TB only2 5 (18%)
Both pulmonary and extrapulmonary TB3 2 (7%)
Not recorded 3 (11%)
TB treatment commenced 27 (96%)
           Basis upon which TB treatment commenced:
Bacteriologically-confirmed Mtb4 11 (41%)
Compatible imaging5 11 (41%)
Compatible symptoms and positive sputum mycobacterial culture 
(later identified as NTM)6
2 (7%)
Not known7 3 (11%)
           Time from substudy entry to treatment start (n=26), days - 
                                                                                       Median (IQR)
49 (0, 108)
Repeat Xpert on stored sputum
Xpert positive 5 (18%)
CXR = chest radiograph; LPA = line probe assay; NTM = Non tuberculous mycobacteria;  
USS = ultrasound scan
1 Includes two participants for whom bacteriological confirmation was provided by stored sputum 
which was Xpert-positive; one of whom started treatment based on this result, and the other had 
already started TB treatment because of compatible chest radiograph (miliary TB).
2 Pleural effusion (3); positive mycobacterial blood culture (1); pericardial effusion (1)
3 Compatible abdominal ultrasound and sputum Mtb culture-positive (1), pleural effusion and 
sputum Xpert positive (1)
4 Sputum Xpert positive (7) of which one was the sample stored for repeat Xpert and samples 
were collected at median 97 days (IQR 79, 118) after substudy entry; sputum Mtb culture-positive 
(3); blood Mtb culture-positive (1)
5 Compatible CXR (9) of which four subsequently bacteriologically confirmed, compatible USS (2)
    •   Case definitions fulfilled for CXR reporting:
            º  7 Probable radiological TB (pleural effusion [4], miliary TB [1], cavitation and infiltrates [2]).
            º 2 Possible radiological TB
    •   USS: Pericardial effusion (1); abdominal TB with subsequent sputum Mtb culture-positive (1)
One participant categorised as probable TB had bilateral pleural effusions and cardiomegaly and 
was reported at verbal autopsy as having started TB treatment based on CXR 
6 Started on basis of compatible symptoms and positive sputum culture later identified as  
M. avium (1) and M. intracellulare (1); both had improvement in symptoms after treatment was 
initiated.
7 Identified as having started TB treatment at verbal autopsy (2), started by clinic doctor (1)
Page 7 of 15
Gates Open Research 2018, 2:22 Last updated: 15 MAY 2019
Figure 2. Number of participants diagnosed with TB by “repeat” Xpert vs. number diagnosed during follow-up (N=28). CXR = chest 
radiograph; USS = ultrasound scan 1 CXR features compatible with “Probable TB” (pleural effusion [4], cavitation and infiltrates [2]); CXR 
features compatible with “Possible TB” (2); USS features compatible with TB (Pericardial effusion [1]; abdominal TB [1]) 2 One participant 
died before treatment commenced 3 Two identified as having started TB treatment at verbal autopsy. One had M. xenopi identified in sputum 
culture prior to commencement of empiric TB treatment. 4 Started on basis of compatible symptoms and positive sputum culture later 
identified as M. avium (1) and M. intracellulare (1); both had improvement in symptoms after treatment was initiated.
repeat Xpert, but did not attain statistical significance, odds ratio 
4.0 (95% CI: 0.8–38.7; p=0.11, McNemar’s test).
The participant who started TB treatment solely based on the 
stored repeat Xpert sample was in the pre-ART group with 
a CD4 cell count of 113 cells/mm3 at substudy enrolment, 
had no previous history of TB treatment, and had a five week 
history of cough and fever when the initial sputum sample for 
Xpert was collected. The sputum culture, the only component of 
the Xpert-negative algorithm arranged at the Xpert review visit, 
was contaminated. This participant initiated ART on the day of 
entry to the substudy, was WHO-tool negative at all subsequent 
study visits, and had negative sputum and blood for mycobacte-
rial culture at the 3-month visit. The remaining four participants 
with positive stored repeat Xpert sample started TB treatment 
before the stored sample was processed, based on further 
evaluation during follow-up: sputum Xpert-positive (2, one with 
rifampicin resistance); sputum Mtb culture-positive (1); and 
compatible chest radiograph (1).
Further evaluation of substudy participants undertaken 
during substudy follow-up
Figure 3 summarises all evaluations undertaken for TB 
during substudy follow-up, aside from 3-month visit mycobac-
terial cultures and Xpert on stored sputum samples. As part of 
routine care or facilitated by research staff for the Xpert- 
negative algorithm, 97/227 (43%) had a chest radiograph 
(38/97 [39%] fulfilled criteria for radiological TB), and 100/227 
(44%) had mycobacterial culture on sputum (3/100 [3%] Mtb 
positive). 34/227 (15%) of participants were prescribed an 
antibiotic trial at the Xpert result review, and 14/21 (67%) of 
those reviewed reported resolution of symptoms.
89 participants submitted sputum specimens for Xpert as part of 
routine care or because they fulfilled XPHACTOR algorithm 
criteria at monthly follow-up visits, for whom 6/89 (7%) were 
positive. An additional four participants had positive Xpert, 
of which three were stored sputum samples for repeat Xpert 
(bacterial confirmation provided solely by stored sample [2], also 
positive Mtb sputum culture [1]), and one was collected after the 
3-month visit (Table 2).
The mycobacterial cultures performed routinely at the 3-month 
visit yielded Mtb isolates in 2% (5/219) of sputum and 0/220 
blood samples.
Performance of urine LAM
LAM results were available for 142/227 (63%) of study par-
ticipants, with a positive result (grade 2 cut-off) observed in 
2/142 (1%). 18/142 (13%) fulfilled case definitions for TB 
(clinical and confirmed). The sensitivity of LF-LAM for TB 
(clinical and confirmed) was 0% and specificity was 98.4% 
(95% CI 94.3, 99.8). Sensitivity and specificity were similar in 
those 175 excluded because they were unable to produce sputum 
(Table 1).
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Figure 3. Evaluation of participants undertaken from repeat Xpert substudy entry to 3-month visit. Categories are not mutually exclusive 
as each participant could undergo >1 mode of evaluation for TB C+ = culture positive; CXR = chest radiograph; ID = final identification; MTB 
= M. tuberculosis; NTM = non-tuberculous mycobacteria. 1 Excludes stored sputum samples for repeat Xpert, and sputum and blood samples 
for mycobacterial culture collected at 3-month visit 2 As part of routine care or facilitated by research staff for GXP-negative algorithm. 97 
participants had 100 CXRs, for those with multiple CXR most recent CXR is reported. 3 Facilitated by research staff for GXP-negative algorithm 
4 As part of routine care or facilitated by research staff as high priority by XPHACTOR study algorithm. 89 participants had 137 sputum 
samples tested with Xpert, for those with multiple samples most recent sample reported. 5 As part of routine care or facilitated by research staff 
for GXP-negative algorithm. 99 participants had 109 sputum samples processed for mycobacterial culture, for those with multiple samples 
most recent sample reported. 6 Reviewed and reported completing at least 5 days of antibiotics
Discussion
Among HIV-positive individuals at high risk of active TB, with 
a negative sputum Xpert result, very few TB diagnoses would 
have been made in this study by immediately repeating Xpert. 
We limited our study to HIV-positive individuals at highest 
risk of active TB, i.e. those who were WHO tool positive with 
CD4<200x106/l, or pre-ART with CD4<200x106/l, or newly 
diagnosed, to minimise unnecessary testing of individuals at 
lower risk of active TB. The low yield from repeat Xpert in 
those with negative initial Xpert is likely due to paucibacillary or 
extrapulmonary disease. These TB diagnoses may be better 
identified by alternative diagnostic modalities, such as chest 
radiography. A South African study of patients with sputum 
screened for TB by Xpert and mycobacterial culture prior to ART 
initiation, using a gold standard of culture-confirmed TB 
(N=85), found that those who were Xpert-negative had higher 
CD4 cell counts and lower viral loads than those who were 
Xpert-positive14. We did not have enough positive stored Xpert 
results to undertake a similar analysis.
Our study illustrates the realities of implementing the test nega-
tive algorithm in HIV-positive individuals. Despite research 
staff facilitating the algorithm, less than half (100/227) of 
participants produced sputum for mycobacterial culture during 
follow-up (vs. 100% assumed by Schnippel)7. We found 
sensitivity of the repeat Xpert was only 18% (5/28) for all TB or 
31% (5/16) for bacteriologically-confirmed TB vs. 79% assumed 
by Schnippel6,7. Data from South Africa demonstrate poor 
adherence in routine care settings to TB diagnostic algorithms 
amongst HIV-positive individuals with initial negative Xpert 
test15,16. The aforementioned model6,7 assumes 1% of patients 
with TB symptoms start TB treatment based on a clinical 
diagnosis, but we found this to be far greater; and the model 
does not consider extrapulmonary TB (one-fifth of our par-
ticipants diagnosed with TB had only extrapulmonary disease). 
An economic evaluation of repeat sputum Xpert vs. the Xpert- 
negative algorithm for HIV-positive individuals using assumptions 
that are more realistic is needed.
Evaluation of the 2007 WHO algorithm for smear-negative TB 
(comprising chest radiograph, single sputum for mycobacte-
rial culture, and antibiotic trial), in HIV-positive individuals 
being investigated for TB in Cambodia17, against a gold 
standard of culture-confirmed TB based on multiple specimens, 
demonstrated sensitivity of 60%17. Sensitivity of this algorithm 
is imperfect, and there is a risk of overtreatment when only 
clinical-radiological features are used to start TB treatment. 40% 
(11/27) of our study participants who started TB treatment did so 
because of compatible imaging, of whom almost half were 
subsequently bacteriologically confirmed, highlighting its value 
to support rapid initiation of TB treatment. Our findings are 
in accord with data from the XTEND trial, which found that 
compatible chest radiograph was the main reason for initiating 
empiric TB treatment in a cohort of patients investigated for TB 
in primary care in South Africa, amongst whom microbiologi-
cal confirmation was subsequently obtained for 13%18. South 
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African national guidelines now recommend chest radiography 
for all individuals with symptoms suggestive of TB who can-
not produce a sputum sample, but limited access to radiography 
facilities may limit implementation4. Amongst our study par-
ticipants who provided sputum for mycobacterial culture prior to 
their 3-month visit there was a low yield of Mtb (3/100 [3%]), 
and the yield from further Xpert during follow-up was 7% 
(6/89), representing just over half (9/16) of all confirmed TB 
diagnoses. Our findings highlight the need for more sensitive 
diagnostic tests, and for repeating TB investigation using all avail-
able modalities, in HIV-positive individuals with initial negative 
sputum test result who remain symptomatic or have advanced 
immunosuppression. Current WHO guidance supports the 
use of urine LF-LAM to assist TB diagnosis in symptomatic 
HIV-positive adult in- or out-patients with CD4 cell counts ≤100 
cells/mm3, or those who are seriously ill irrespective of CD4 
count13. Data from the STAMP trial showed that systematic 
screening with LF-LAM of hospitalised HIV-positive adults 
increased overall TB diagnosis and in certain subgroups of 
patients reduced mortality19. We have previously reported the 
low sensitivity of LF-LAM in the broader XPHACTOR study 
population20. In this substudy we found that LF-LAM would 
not have helped make earlier diagnoses of TB.
Our study has some limitations. In the parent XPHACTOR study, 
Xpert testing was prioritised in people with BMI<18.5kg/m2 
or CD4<100, those newly diagnosed HIV-positive or pre-ART 
with CD4<200, as well as those with TB symptoms8. Thus the 
population in this substudy did not all have classic “TB symp-
toms” at the time of collection of either initial or repeat sputum 
samples for testing with Xpert. However, TB prevalence in our 
substudy population was high, and we anticipate our results to 
be relevant at least to these high-risk groups. We froze all our 
raw sputum samples within 24 hours of collection, and all were 
thawed and tested within 6 months of collection, in line with 
other studies21. We assumed that all participants starting TB 
treatment or with a sample which was bacteriologically 
confirmed collected within six months of enrolment were likely 
to have had active TB at enrolment, regardless of whether it was 
diagnosable using sputum based tests at the time of enrolment. 
In fact, our study participants who started TB treatment com-
menced within a median of seven weeks from collection of the 
“repeat” Xpert sample. Some sputum samples for mycobacte-
rial culture and chest radiographs were taken at an interval after 
participants returned for their initial Xpert test result, reflect-
ing real-life investigation practice; we cannot be certain of the 
same result if they had been performed at the same time as 
sample collection for repeat Xpert. However, our findings 
suggest that following the Xpert-negative algorithm is more 
likely to lead to TB diagnosis than immediate repeat Xpert test.
Strengths of our study include systematic evaluation of par-
ticipants and longitudinal follow-up which minimised the 
number of TB diagnoses missed, and the pragmatic nature of the 
study which reflected as far as possible real-life conditions, albeit 
with optimised implementation of TB diagnostic algorithms.
Conclusions
Amongst ambulatory HIV-positive individuals at high risk of 
active TB, if an initial Xpert is negative, the Xpert-negative path-
way should be implemented and there should be a low threshold 
for investigating those who remain at high risk using all clinically 
appropriate diagnostic modalities. In addition, those for whom no 
TB diagnosis is made must be made aware of the importance of 
returning for review if symptoms persist or recur. Our findings do 
not support sending an immediate repeat Xpert and highlight the 
need for more sensitive diagnostic tests capable of detecting pulmo-
nary and extrapulmonary TB.
Data availability
The XPHACTOR “Investigating TB if initial Xpert is negative” 
dataset, which includes data underlying this substudy, has been 
uploaded to the LSHTM Data Compass repository: https://doi.
org/10.17037/DATA.28422.
The reader will need to request the dataset from LSHTM (request 
access is provided within the data record) with a brief summary of 
how the dataset will be utilised. On request, a data sharing agree-
ment will be made available which will first need to be signed, prior 
to provision of the dataset. This enables LSHTM to confirm that 
the reader is using the data for HIV or TB-related research, which 
is required because study participants consented to use of their data 
for HIV or TB-related research only.
The data is shared under a Data Sharing Agreement license (see 
above).
The study team wish to avoid unnecessary barriers to access and 
will seek to respond to data requests as quickly as possible.
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Overall
This study provides some interesting data on how useful a 2nd Xpert is to follow-up on those
initially negative by Xpert. The addition of LAM to this study needs to be clearly and explicitly
explained. Currently it reads as a very extraneous add-on.
 
There are too many tables/figures for the amount of actual data. I find the presentation of data
currently to be excessive and unnecessarily complicated and duplicative.
Introduction:
Aim is awkwardly stated. Possibly reword with study population at the end, and try to make it more
succinct.
 
LAM needs to be included as an aim from the start. Otherwise it feels like a very tangential add on.
Methods:
I would like a formal definition of the primary outcome and any secondary outcomes. They are
probably in there, but not explicitly stated enough.
 
I think a flow diagram of testing would be helpful to flesh out the methods.
 
It's not clear to me where LAM fits in. An Xpert negative pt is re-screened for symptoms, has a
chest x-ray and sputum for culture, and/or antibiotic trial is given. But then suddenly under
statistical methods, you mention LAM for the first time. LAM is not part of the SA algorithm. We
need to know when this was done, and even why it is relevant to this study.
Results:
Not sure why 1 person who started TB treatment >6 months after enrollment would be excluded?
This gets back to my previous point that you need to explicitly state the primary outcome, so we
can understand why you would have excluded these 7 individuals.
 
I'm confused by figure 1. What i'd like to know is what is the additional yield of Xpert, but I can't tell
that from this figure. The way it looks is that all the people who had confirmed TB were not
diagnosed with clinical TB. However, I can't believe that is true. I would prefer to see who was
diagnosed how up front  (clinical, microbiological) and who wasn't ("not tb"). Then from those
boxes, show us how many in each were Xpert positive from the 2nd sputum.
 
I'm confused by the section on TB diagnosis. Those diagnosed by Xpert don't appear to be by the
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I'm confused by the section on TB diagnosis. Those diagnosed by Xpert don't appear to be by the
2nd Xpert that was taken and stored, because lower down you detail those individuals. But a 2nd
Xpert is not part of the SA algorithm.  Something needs to be done to make this clearer.
 
Table 2 confuses me for the same reason that figure 1 confuses me.
 
If you change figure 1 as suggested above, then you don't need a venn diagram. That diagram
conveys very little information.
 
Figure 3 is totally confusing because people can be in more than one of the top boxes...I'm not sure
what this adds, particularly how it speaks to your primary outcome.
Discussion:
Although the authors note that their population was not limited to symptomatic individuals as a
potential weakness, they do not explicitly state that an asymptomatic population is likely to have
paucibacillary or subclinical disease, for which Xpert would not have good sensitivity. The SA
algorithm for TB investigation starts with a positive symptom screen, not merely for being HIV
positive with a low CD4 despite having no symptoms. So these findings are not necessarily
generalizeable to actual practice.
 
I would also note that the prevalence of clinical diagnosis is not necessarily generalizeable. Its
unclear the level of care that was given to these participants- was this routine care available in a
primary public health clinic, or is this specialized care as part of a research study? These details
could help the reader evaluate how generalizeable the findings are.
Conclusions:
The reference to the "Xpert negative pathway" is vague - authors should be specific about what
kinds of followup are most useful. Authors should also include something about LAM.
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Partly
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
 No competing interests were disclosed.Competing Interests:
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
Page 14 of 15
Gates Open Research 2018, 2:22 Last updated: 15 MAY 2019
Gates Open Research
 
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
Page 15 of 15
Gates Open Research 2018, 2:22 Last updated: 15 MAY 2019
